Table 5.

Medical oncology priorities: locally advanced disease

High priority	Medium priority	Low priority
Concomitant chemo-radiotherapy for SCLC limited disease stage III
Concomitant or sequential chemo-radiotherapy for inoperable NSCLC Stage III
Starting consolidation durvalumab (within 42 days)
Neoadjuvant chemotherapy in clinical stage III	Medical follow-up between two cycles should be performed only if necessary and by telephone
G-CSF use if febrile neutropenia risk evaluated more than 10% to 15%	Laboratory check during treatment should be performed only if necessary and at home if possible

G-CSF, granulocyte colony-stimulating factor; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.